Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Clinical evidence

Pooled phase I/II analysis versus external control

85 evidence topics · 20 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using cUHDRS change at 36 months as the primary endpoint
Components of the cUHDRS as described by the sponsor
Statistical analysis description
Number of participants (Planned and analyzed)
Participants with data at each visit in the three-year analysis, high dose
Group and endpointBaseline12 months24 months36 months
AMT-130 high dose (cUHDRS and TFC)“17”“17”“15”“12”
PSM external control, cUHDRS“940”“715”“586”“568”
PSM external control, TFC“940”“725”“597”“583”
Participants with data at each visit in the four-year analysis, high dose
Group and endpointBaseline12 months24 months36 months48 months
AMT-130 high dose (cUHDRS and TFC)“17”“17”“15”“15”“12”
Enroll-HD B, cUHDRS“1337”“953”“760”“690”“625”
Enroll-HD B, TFC“1337”“967”“772”“704”“641”
Enroll-HD A, cUHDRS (post hoc)“619”“484”“398”“355”“349”
Enroll-HD A, TFC (post hoc)“619”“492”“401”“360”“364”
Participants with cerebrospinal fluid neurofilament light chain samples, through 48 months
Description of analysis sets
Derivation of the Enroll-HD external control arm analysis set
StepParticipants
Diagnosis of HD in ENROLL-HD“N = 19,542”
Met AMT-130 eligibility criteria“N = 6,596 (33.8%)”
Did not meet AMT-130 eligibility criteria“N = 12,946”
Excluded from the analysis set“N = 3,326”
External control arm analysis set“N = 3,270 (49.6%)”
Propensity-score matched to High-Dose cohort“N = 940”
Results
Participant disposition
Baseline characteristics
Demographic and baseline characteristics of the high-dose cohort and the propensity score-matched external control
Characteristic, mean (SD)AMT-130 high dose (N=17)PSM external control, Enroll-HD (N=940)
Sex, males (%)“47.1”“55.6”
Age“45.8”“45.2”
CAG repeats“42.4”“42.8”
CAP100 score“86.2”“86.8”
DCL = 3, 4 (%)“35.3, 64.7”“30.5, 69.5”
PIN score“0.77”“0.81”
cUHDRS“14.9”“14.7”
TFC“12.2”“12.1”
SDMT“46.1”“45.3”
SWRT“89.9”“87.6”
TMS“12.1”“11.6”
HD-ISS Stage 2, 3 (%)“47.1, 52.9”“51.6, 48.4”
Region; No. America, Other (%)“58.8, 41.2”“28.9, 71.1”
Efficacy results
Cerebrospinal fluid neurofilament light chain at 2 and 3 years, high dose
TimepointParticipantsCSF NfL mean change from baseline
Year 2“N = 15”“-9.7%”
Year 3“N = 11”“-8.2%”
Primary analysis at 48 months: other secondary endpoints, high dose
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events in Cohorts 1 to 3, June 2025 data cutoff
Adverse event, N (%)Sham surgery (n=10)Low-dose AMT-130, Cohort 1 (n=13)High-dose AMT-130, Cohort 2 (n=20)Dose-blinded, Cohort 3 (n=12)All AMT-130, Cohorts 1, 2 and 3 (n=45)
Any TEAEs“10”( “100.0”)“12”( “92.3”)“20”( “100.0”)“12”( “100”)“44”( “97.8”)
Any SAEs“1”( “10.0”)“3”( “23.1”)“9”( “45.0”)“3”( “25”)“15”( “33.3”)
Any SAEs (peri-operative)“1”( “10.0”)“2”( “15.4”)“6”( “30.0”)“0”( “0.0”)“8”( “17.8”)
Any drug-related TEAE“0”( “0.0”)“0”( “0.0”)“6”( “30.0”)“3”( “25.0”)“9”( “20.0”)
Any drug-related SAE“0”( “0.0”)“0”( “0.0”)“4”( “20.0”)“0”( “0.0”)“4”( “8.8”)
Headache“3”( “30.0”)“3”( “23.1”)“9”( “45.0”)“6”( “50.0”)“18”( “40.0”)
Procedural headache“5”( “50.0”)“4”( “30.8”)“10”( “50.0”)“2”( “16.7”)“16”( “35.6”)
Procedural pain“6”( “60.0”)“2”( “15.4”)“7”( “35.0”)“2”( “16.7”)“11”( “24.4”)
Post lumbar puncture syndrome“6”( “60.0”)“2”( “15.4”)“5”( “25.0”)“2”( “16.7”)“10”( “22.2”)
Procedural complication“4”( “40.0”)“4”( “30.8”)“5”( “25.0”)“0”( “0.0”)“9”( “20.0”)
Anxiety“0”( “0.0”)“0”( “0.0”)“4”( “20.0”)“4”( “33.3”)“8”( “17.8”)
Constipation“0”( “0.0”)“0”( “0.0”)“2”( “10.0”)“6”( “50.0”)“8”( “17.8”)
Insomnia“0”( “0.0”)“1”( “7.7”)“1”( “5.0”)“6”( “50.0”)“8”( “17.8”)
Back pain“1”( “10.0”)“0”( “0.0”)“0”( “0.0”)“5”( “41.7”)“5”( “11.1”)
Adverse events in all 51 treated participants, June 2026 data cutoff
Adverse event, N (%)Sham surgery (n=10)Low-dose AMT-130, Cohort 1 (n=13)High-dose AMT-130, Cohort 2 (n=20)Dose-blinded AMT-130, Cohort 3 (n=12)High-dose AMT-130, Cohort 4 (n=6)All AMT-130, Cohorts 1, 2, 3 and 4 (n=51)
Any TEAEs“10”( “100.0”)“12”( “92.3”)“20”( “100.0”)“12”( “100”)“6”( “100”)“50”( “98”)
Any SAEs“1”( “10.0”)“4”( “30.8”)“10”( “50.0”)“4”( “33.3”)“2”( “33”)“20”( “39.2”)
Any SAEs (peri-operative)“1”( “10.0”)“2”( “15.4”)“6”( “30.0”)“0”( “0.0”)“1”( “16.7”)“9”( “17.6”)
Any drug-related TEAE“0”( “0.0”)“0”( “0.0”)“6”( “30.0”)“3”( “25.0”)“2”( “33.3”)“11”( “21.5”)
Any drug-related SAE“0”( “0.0”)“0”( “0.0”)“4”( “20.0”)“0”( “0.0”)“1”( “16.7”)“5”( “9.80”)
Headache“3”( “30.0”)“2”( “15.4”)“9”( “45.0”)“6”( “50.0”)“4”( “66.7”)“21”( “41.2”)
Procedural headache“5”( “50.0”)“4”( “30.8”)“10”( “50.0”)“2”( “16.7”)“0”( “0.0”)“16”( “31.4”)
Procedural pain“6”( “60.0”)“2”( “15.4”)“7”( “35.0”)“3”( “25.0”)“1”( “16.7”)“13”( “25.5”)
Post lumbar puncture syndrome“6”( “60.0”)“2”( “15.4”)“6”( “30.0”)“2”( “16.7”)“0”( “0.0”)“10”( “19.6”)
Procedural complication“4”( “40.0”)“3”( “23.1”)“4”( “20.0”)“0”( “0.0”)“0”( “0.0”)“7”( “13.7”)
Anxiety“0”( “0.0”)“0”( “0.0”)“4”( “20.0”)“4”( “33.3”)“3”( “50.0”)“11”( “21.6”)
Constipation“0”( “0.0”)“0”( “0.0”)“2”( “10.0”)“6”( “50.0”)“1”( “16.7”)“9”( “17.6”)
Insomnia“0”( “0.0”)“1”( “7.7”)“1”( “5.0”)“6”( “50.0”)“2”( “33.3”)“10”( “19.6”)
Back pain“1”( “10.0”)“0”( “0.0”)“0”( “0.0”)“5”( “41.7”)“0”( “0.0”)“5”( “9.8”)
Procedural nausea“0”( “0.0”)“3”( “23.1”)“3”( “15.0”)“1”( “8.3”)“2”( “33.3”)“9”( “17.6”)
Paraesthesia“1”( “10.0”)“0”( “0.0”)“1”( “5.0”)“1”( “8.3”)“2”( “33.3”)“4”( “7.8”)
Sleep disorder“0”( “0.0”)“0”( “0.0”)“0”( “0.0”)“4”( “33.3”)“0”( “0.0”)“4”( “7.8”)
Sensory loss“0”( “0.0”)“0”( “0.0”)“0”( “0.0”)“1”( “8.3”)“2”( “33.3”)“3”( “5.9”)
Study limitations
Summary
  • External comparison: efficacy is assessed against a propensity score-matched external control from the Enroll-HD natural history data set. The Form 10-K states that the analyses rely on external historical controls and that these may not be accepted as a basis for regulatory approval. After a Type A meeting in January 2026, the FDA stated that it cannot agree that these data are sufficient as primary evidence of effectiveness. One commentary noted that the evidence of efficacy “depends entirely on the ENROLL-HD controls being well-matched”.
  • Open-label treatment: the same commentary noted that most participants were in open-label arms, so a placebo effect is possible. An analysis of the GENERATION HD1 placebo arm found a placebo response on the cognitive scores (SDMT and SWR), which also influences the cUHDRS.
  • Matching covariates: MRI data were not collected in Enroll-HD, so striatal volume, a predictor of decline and an eligibility criterion of the phase I/II studies, could not be matched. The sponsor analysis used baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, and SWR and reports that other covariates can substitute for striatal volume. A comment submitted to ICER listed limits of the natural history comparison, including bias from selection into a surgical trial versus a registry, different visit schedules, and very small numbers of treated patients at longer follow-up.
  • Small numbers: 12 high-dose participants contributed 36-month data to the three-year analysis, 15 to the updated 36-month analysis, and 12 to the 48-month analysis; CSF NfL was available for 11 high-dose participants at 36 months in the three-year analysis.
  • Missing data and changes in the control: missingness in the updated Enroll-HD matched controls reached 53% at 48 months, controls with longer follow-up declined more slowly, and decline in Enroll-HD B was 20% slower than in Enroll-HD A at 48 months. Against Enroll-HD B the 48-month cUHDRS result did not reach statistical significance (p=0.144); the result against Enroll-HD A comes from a post-hoc sensitivity analysis. A news report on the four-year analysis noted that the natural history database is updated, which “can alter results”.
  • Analysis choices and nominal p-values: the June 2025 release described a propensity score-weighted primary analysis, while the September 2025 release reports the propensity score-matched comparison as the prespecified primary analysis. The 24-month comparison with a propensity-weighted external control of 154 participants was a post-hoc analysis. Several p-values are nominal, which the Form 10-K states regulators may weigh less than standard p-values.
  • Reporting: the results are reported in company press releases, presentations, and SEC filings. One commentary noted that individual data points are not shown, error bars are not defined, data from imitation (sham) procedure participants are not shown, and there are no data on mutant HTT lowering.
Missing data and survivor bias in the updated Enroll-HD external control
Enroll-HD B participants, by last available dataAnnualized cUHDRS change from baseline
Participants with last data at Y1“-0.91”
Participants with last data at Y2“-0.82”
Participants with last data at Y3“-0.73”
Participants with last data at Y4 or more“-0.41”
Effect of volumetric criteria on 3-year decline in TRACK-HD, TRACK-ON, and PREDICT-HD
AnalysisVolumetric criteria applied (N = 232)Volumetric criteria not applied (N = 442)
cUHDRS mean change from baseline to 3 years, unweighted“-1.4”“-1.7”
cUHDRS mean change from baseline to 3 years, PS weighted“-1.4”“-1.4”
TFC mean change from baseline to 3 years, unweighted“-1.0”“-1.2”
TFC mean change from baseline to 3 years, PS weighted“-0.9”“-0.9”